Literature DB >> 35611250

Preoperative esophagogastroduodenoscopy findings and effects on laparoscopic Roux-en-Y gastric bypass in area with high prevalence of Helicobacter pylori infection: multi-center experience in Iran.

Mehdi Alimadadi1, Seyedali Seyedmajidi2, Sina Safamanesh3, Elena Zanganeh1, Seyed Ashkan Hosseini4, Shahin Hajiebrahimi1, Mohammadreza Seyyedmajidi1.   

Abstract

Aim: The current study aimed to evaluate EGD findings effects on laparoscopic Roux-en-Y gastric bypass (RYGB) plan and time in areas with a high prevalence of Helicobacter pylori infection. Background: Esophagogastroduodenoscopy (EGD) and Helicobacter pylori testing are routine parts of preoperative assessment of bariatric surgery at many centers.
Methods: This was a crosssectional study of all patients underwent EGD and histopathological examination before laparoscopic RYGB in three gastroenterology centers in Iran between January 2018 and December 2020.
Results: In total, 637 patients (52.4% female) were enrolled, of which 46.8% had no abnormal mucosal appearance. In 1.7%, surgery was canceled (gastric adenocarcinoma, gastric intestinal metaplasia, GIST, and esophageal varices). The prevalence of H. pylori was 61.5%, and there was no statistical difference between groups of normal and abnormal EGD; however, surgery was postponed after H. pylori eradication in both groups. Overall, 44.4% of patients with esophagitis (any grade), peptic ulcer disease, erosive and non-erosive gastritis/duodenitis, and short segment Barret's esophagus needed medical management. Small- or medium-sized sliding hiatal hernias were seen in 18.7% of patients with no effect on surgery. Moreover, 88.8% of patients with normal mucosal appearance were asymptomatic, but 92.6% in the group with abnormal EGD were symptomatic (p=0.01). Changes in surgical plan and time occurred in 63.6%, but after eliminating H. pylori eradication, it was 15.4%.
Conclusion: Considering gastric cancer and the high prevalence of H. pylori in Iran, using EGD and histopathological examination as an investigation in the preoperative assessment would have a significant impact on patients undergoing RYGB surgery. ©2022 RIGLD, Research Institute for Gastroenterology and Liver Diseases.

Entities:  

Keywords:  Esophagogastroduodenoscopy; Gastric bypass surgery; Helicobacter pylori

Year:  2022        PMID: 35611250      PMCID: PMC9123628     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol Bed Bench        ISSN: 2008-2258


Introduction

Obesity has become a common health problem all over the world and its prevalence is increasing in both developed and developing countries. Obesity and overweight are the world's fifth cause of mortality, and 2.6 million people die due to this disorder annually (1). Therefore, it is probable that the most important of risk factors fulfill the criteria for being governmental health priorities. In 2016, the national prevalence rates of normal weight, obesity, and overweight/obesity in Iranian adults were estimated at 36.7%, 22.7%, and 59.3%, respectively (2). One analysis in Iran showed that 33.78%, 10.25%, and 30.56% of cases of the prevalent diabetes mellitus were attributable to overweight (Body Mass Index: BMI ≥ 25 kg/m2), general obesity (BMI ≥ 30 kg/m2), and central obesity (waist circumference ≥ 90 cm), respectively (3). Conservative management of obesity can only induce a nearly 10% weight loss and may provide cardiac and metabolic benefits (4). However, the American Society for Metabolic and Bariatric Surgery (ASMBS) recommended bariatric surgery for patients with a BMI ≥ 40 with or without coexisting comorbidities, and for those with a BMI ≥ 35 with severe obesityrelated medical conditions or remarkably impaired quality of life (5). The evaluation before bariatric surgery consists of history taking, physical examination, laboratory tests, psychology, endocrine, cardiopulmonary, and gastrointestinal (GI) assessments. The GI evaluation might include screening for Helicobacter pylori (H. pylori) in high prevalence areas, or if clinically indicated, and esophagogastroduodenoscopy (EGD) (5). This practice evaluated endoscopic findings, H. pylori status, and histopathological examination in the preoperative assessment of patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) in Iran with a high prevalence of H. pylori.

Methods

This study was a crosssectional evaluation of all patients who underwent upper GI endoscopy before laparoscopic RYGB surgery in three gastroenterology clinics in Iran (Gorgan, Tehran, and Mashhad) between January 2018 and December 2020 (3 years). EGDs were done and two specimens were obtained from the antrum to assess Helicobacter pylori status and histopathological examination. All participants signed an informed consent form. History taking, physical examination. and patients’ data collected included age, gender, BMI, H. pylori status, EGD and histopathological results as outcome variables. All data was analyzed using Statistical Package for Social Sciences Ver.20 (SPSS, IBM Corp.; Armonk, NY, USA). The values were expressed as mean ± standard deviation (SD) for continuous variables and percentages for categorical variables. The normality of distribution of data was assessed using the Kolmogorov-Smirnov test. Patients’ endoscopic findings on the basis of sex, BMI * Los Angeles classification Correlation between H. pylori status and endoscopic findings Correlation between upper GI symptoms & signs and endoscopic findings

Results

A total of 637 patients, of whom 332 (52.4%) were female, were referred to the endoscopy units for preoperative EGD before laparoscopic RYGB surgery. Participants’ age ranged between 19 and 52 years with a mean ± SD of 34.4 ± 9.2 years. The average BMI and SD of patients was 45.1 ± 7.3 kg/m2. Patients’ endoscopic findings on the basis of sex and BMI are displayed in Table 1. There were no statistical differences in sex and BMI between groups of EGD findings.
Table 1

Patients’ endoscopic findings on the basis of sex, BMI

Endoscopic findingsSexBMITotal
malefemale p. value35≤BMI<4040≤BMI p. value
Normal mucosal appearance1481910.201611780.35339
Esophagitis(LA* A & B)30260.5927290.7856
Esophagitis(LA C & D)120.56120.563
Barret’s esophagus430.70340.707
Esophageal varices11-02-2
Non-erosivegastritis / duodenitis74700.7379650.24144
Erosivegastritis/ duodenitis22180.5219210.7540
Gastric / duodenal ulcers19140.3818150.6033
Gastric polyps450.73540.739
Gastric bezoar11-11-2
Gastric adenocarcinoma10-10-1
Gastrointestinal Stromal Tumor (GIST)01-10-1
Total3053320.283163210.843637

* Los Angeles classification

In 119 EGDs (18.7%), small- or medium-sized sliding hiatal hernias were seen without effect on surgery plan or time. The pathology reports (Table 2) showed that the prevalence of H. pylori in patients with normal EGD, abnormal mucosal appearance, and in total cases was 61.4%, 61.7%, and 61.5%, respectively (p=0.74). Surgery was postponed after H. pylori eradication.
Table 2

Correlation between H. pylori status and endoscopic findings

H. pylori statusNormal mucosal appearanceAbnormal mucosal appearanceTotal
Positive208 (61.4%)184 (61.7%)392 (61.5%)
Negative131 (38.6%)114 (38.3%)245 (38.5%)
Total339298637
Without considering H. pylori status and sliding hiatal hernia, the patients were categorized into four groups according to the endoscopic and histopathologic results: Normal EGD In all, 53.2% of patients had no abnormalities in EGD and histopathological examination. Minor abnormal findings On the basis of Los Angeles (LA) classification, esophagitis LA (A & B) and non-erosive gastritis / duodenitis were seen in 8.8% and 22.6%, respectively. Seven individuals had short segment Barret’s esophagus without dysplasia that did not change the plan of surgery. Nine patients had few tiny polyps in stomach all of which were hyperplastic in pathology and removed totally by EGD before surgery. Gastric phytobezoars were seen in 2 cases and were successfully removed with endoscopic intervention and before surgery. Gastric motility disorders were ruled out with gastric emptying scintigraphy. Major abnormal findings Esophagitis LA (C & D), erosive gastritis/ duodenitis and peptic ulcers were seen in 0.4%, 6.3%, and 5.2%, respectively. In these patients, surgery was postponed at least 3 months to complete treatment and repeat EGD. Findings that were considered contraindications for surgery Eleven patients (1.7%) in the current sample were found to have pathologies that were considered contraindications for surgery. Two patients had esophageal varices, one had malignant ulcer in the lesser curvature of the gastric body, and one had gastrointestinal stromal tumor (GIST) in the gastric fundus. In seven patients, histopathological examination of the antrum showed intestinal metaplasia without dysplasia; therefore, surgery was cancelled for surveillance EGD. In Table 3, 88.8% of patients with normal mucosal appearance in EGD were found to be asymptomatic, but only 7.4% in the group with abnormal EGD (p=0.01) had this result. Changes in surgical plan and time occurred in 63.6% cases, but only in 15.4% after eliminating H. pylori status.
Table 3

Correlation between upper GI symptoms & signs and endoscopic findings

Upper GI symptoms & signsNormal mucosal appearanceAbnormal mucosal appearanceTotal
Positive38 (11.2%)276 (92.6%)314 (49.3%)
Negative301 (88.8%)22 (7.4%)323 (50.7%)
Total339298637

Discussion

In the past, European guidelines recommended routine EGD in the preoperative assessment of bariatric surgery, while North American guidelines recommended a selective approach (6, 7). Now, however, clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery (update 2020) have no recommendation for routine H. pylori eradication and conditional recommendation for EGD as a diagnostic test prior to bariatric surgery on the basis of available evidence. This panel provided that selective endoscopy in patients with upper abdominal symptoms might be more appropriate (8). One meta-analysis that included 12,261 patients showed that the proportion of EGD findings in changing surgical management was only 7.8%, and after discarding benign findings, this was 0.4%. Changing in medical management was 27.5%, but after eliminating H. pylori eradication, this was 2.5% (6). On this topic, two more systematic reviews were available. The first one including 6845 patients, and suggested changes in surgical management after EGD in 7.8% included delays in surgery due to gastritis or peptic ulcer disease, major changes in the planned procedure, and additional EGD for suspicious lesions. The second meta-analysis of 20 studies on 5140 patients found a management change in 27.5% after EGD. Changes in medical management included H. pylori eradication and initiation of proton-pump inhibitors or histamine blockers (9, 10). The main reason for H. pylori screening in patients undergoing bariatric surgery was to minimize postoperative complications such as marginal ulcers and viscus perforation (11, 12). The multivariable analysis of one cohort found H. pylori status to be the most important independent predictor of marginal ulceration in patients undergoing RYGB, but it had little impact on the outcome of bariatric operations (13). Two other meta-analyses reported that the odds for marginal ulcer and postoperative complications after bariatric surgery were similar for H. pylori-positive versus H. pylori-negative patients. Similarly, there was no firm evidence on postoperative bleeding or leakage (14, 15). This is reflected in a conditional recommendation for routine H. pylori eradication (8). In this survey, a consecutive 637 patients who referred to the endoscopy units for preoperative EGD were analyzed. Similar to many previous studies (7, 16, 17, 18), the number of patients who had any abnormal mucosal appearance was 46.8%. Gastric cancer (GC) is one of the most common cancers in Iran. According to a recent systematic review (19), the prevalence of GC in Iran is between 0.2 and 100 per 100,000 with the death rate per 100,000 people ranging from 10.6 to 15.72. The incidence of GC in patients with H. pylori infection was 18 times higher than other populations. Low economic level and food insecurity increased the odds of GC. In 1.7% of cases in the current study, surgery was canceled due to gastric adenocarcinoma, gastric intestinal metaplasia, GIST, and esophageal varices. The prevalence of H. pylori in the current study was about 61.5%, and there was no statistical difference in prevalence between groups of normal and abnormal EGD findings, but surgery was postponed after H. pylori eradication in both groups. Overall, 283 patients (44.4%) with esophagitis (any grade), peptic ulcer disease, erosive and non-erosive gastritis/ duodenitis, and short segment Barret’s esophagus needed treatment with proton pomp inhibitors or histamine-2 receptor antagonists. Eleven patients (1.7%) needed endoscopic intervention (gastric polyps and bezoars). Small- or medium-sized sliding hiatal hernias were seen in 18.7% without effect on surgery. Many authors have documented a lack of correlation between patients’ symptoms and endoscopic abnormalities (16), but herein, it was found that 88.8% of patients with normal mucosal appearance in EGD were asymptomatic, and 92.6% in the group with abnormal EGD were symptomatic (p=0.01). Changes in surgical plan and time was 63.6%, but after eliminating H. pylori eradication, EGD influenced surgery time in 13.7% and surgery cancellation in 1.7% of cases. In conclusion, considering gastric cancer and the high estimates of H. pylori prevalence in Iran, using EGD and histopathological examination as investigations in the preoperative assessment would have a significant impact on patients undergoing RYGB surgery. Particularly, if clinically symptoms and/or signs are present, the patient should go through an appropriate evaluation.

Conflict of interests

The authors declare that they have no conflict of interest.
  16 in total

1.  Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists.

Authors:  Jeffrey I Mechanick; Caroline Apovian; Stacy Brethauer; W Timothy Garvey; Aaron M Joffe; Julie Kim; Robert F Kushner; Richard Lindquist; Rachel Pessah-Pollack; Jennifer Seger; Richard D Urman; Stephanie Adams; John B Cleek; Riccardo Correa; M Kathleen Figaro; Karen Flanders; Jayleen Grams; Daniel L Hurley; Shanu Kothari; Michael V Seger; Christopher D Still
Journal:  Surg Obes Relat Dis       Date:  2019-10-31       Impact factor: 4.734

2.  Upper Gastrointestinal Endoscopy prior to Bariatric Surgery-Mandatory or Expendable? An Analysis of 801 Cases.

Authors:  Stefan Wolter; Anna Duprée; Jameel Miro; Cornelia Schroeder; Marie-Isabelle Jansen; Clarissa Schulze-Zur-Wiesch; Stefan Groth; Jakob Izbicki; Oliver Mann; Philipp Busch
Journal:  Obes Surg       Date:  2017-08       Impact factor: 4.129

3.  Influence of Helicobacter pylori infection on gastrointestinal symptoms and complications in bariatric surgery patients: a review and meta-analysis.

Authors:  Hendrika J M Smelt; Johannes F Smulders; Lennard P L Gilissen; Mohammed Said; Surendra Ugale; Sjaak Pouwels
Journal:  Surg Obes Relat Dis       Date:  2018-07-21       Impact factor: 4.734

4.  H. Pylori as a predictor of marginal ulceration: A nationwide analysis.

Authors:  Allison R Schulman; Marwan S Abougergi; Christopher C Thompson
Journal:  Obesity (Silver Spring)       Date:  2017-03       Impact factor: 5.002

5.  Flexible endoscopy in the management of patients undergoing Roux-en-Y gastric bypass.

Authors:  Bruce Schirmer; Cengiz Erenoglu; Anna Miller
Journal:  Obes Surg       Date:  2002-10       Impact factor: 4.129

6.  Screening endoscopy before bariatric surgery: a series of 448 patients.

Authors:  Mark Loewen; Jeanine Giovanni; Carlos Barba
Journal:  Surg Obes Relat Dis       Date:  2008-06-02       Impact factor: 4.734

7.  Clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery: update 2020 endorsed by IFSO-EC, EASO and ESPCOP.

Authors:  Nicola Di Lorenzo; Stavros A Antoniou; Rachel L Batterham; Luca Busetto; Daniela Godoroja; Angelo Iossa; Francesco M Carrano; Ferdinando Agresta; Isaias Alarçon; Carmil Azran; Nicole Bouvy; Carmen Balaguè Ponz; Maura Buza; Catalin Copaescu; Maurizio De Luca; Dror Dicker; Angelo Di Vincenzo; Daniel M Felsenreich; Nader K Francis; Martin Fried; Berta Gonzalo Prats; David Goitein; Jason C G Halford; Jitka Herlesova; Marina Kalogridaki; Hans Ket; Salvador Morales-Conde; Giacomo Piatto; Gerhard Prager; Suzanne Pruijssers; Andrea Pucci; Shlomi Rayman; Eugenia Romano; Sergi Sanchez-Cordero; Ramon Vilallonga; Gianfranco Silecchia
Journal:  Surg Endosc       Date:  2020-04-23       Impact factor: 4.584

8.  The utility of esophagogastroduodenoscopy and Helicobacter pylori screening in the preoperative assessment of patients undergoing bariatric surgery: A cross-sectional, single-center study in Saudi Arabia.

Authors:  Ahmad AlEid; Areej Al Balkhi; Ali Hummedi; Anfal Alshaya; Muhammad Abukhater; Abdullah Al Mtawa; Abdullah Al Khathlan; Adel Qutub; Khalid Al Sayari; Shameem Ahmad; Tauseef Azhar; Nawaf Al Otaibi; Ahmed Al Ghamdi; Abed Al Lehibi
Journal:  Saudi J Gastroenterol       Date:  2020 Jan-Feb       Impact factor: 2.485

9.  Patterns of Obesity and Overweight in the Iranian Population: Findings of STEPs 2016.

Authors:  Shirin Djalalinia; Sahar Saeedi Moghaddam; Ali Sheidaei; Nazila Rezaei; Seyed Sina Naghibi Iravani; Mitra Modirian; Hossein Zokaei; Moein Yoosefi; Kimiya Gohari; Ahmad Kousha; Zhaleh Abdi; Shohreh Naderimagham; Ahmad Reza Soroush; Bagher Larijani; Farshad Farzadfar
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-26       Impact factor: 5.555

Review 10.  Epidemiologic Study of Gastric Cancer in Iran: A Systematic Review.

Authors:  Khadijeh Kalan Farmanfarma; Neda Mahdavifar; Soheil Hassanipour; Hamid Salehiniya
Journal:  Clin Exp Gastroenterol       Date:  2020-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.